A dose-expansion part of the same study assessed antitumor activity in patients with NSCLC with high or moderate CEACAM5 expression and demonstrated promising antitumor results in the high CEACAM5 expression cohort (14, 15). The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.